Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Sepantronium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC5 | O15392 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | SP1 | P08047 | 1/20 | 1.00 |
| ▸ | ILF3 | Q12906 | 1/20 | 1.00 |
| ▸ | PAK1 | Q13153 | 1/20 | 1.00 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
| ▸ | CCND2 | P30279 | 1/20 | 0.34 |
| ▸ | CCND3 | P30281 | 1/20 | 0.34 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sepantronium SCHEMBL727997 | 1.00 | BIRC5 (1.00) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL2814447 | 0.99 | BIRC5 (0.98) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL2814857 | 0.99 | BIRC5 (0.98) | BIRC5RIPK2SP1ILF3PAK1 | |
| Bromide SCHEMBL15062823 | 0.89 | BIRC5 (0.79) | BIRC5RIPK2SP1ILF3PAK1 | |
| SCHEMBL6190071 | 0.86 | BIRC5 (0.74) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL16584072 | 0.84 | BIRC5 (0.73) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL29379252 | 0.84 | BIRC5 (0.73) | BIRC5RIPK2SP1ILF3PAK1 | |
| SCHEMBL6190207 | 0.84 | BIRC5 (0.72) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL29464041 | 0.83 | BIRC5 (0.71) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL6188375 | 0.83 | BIRC5 (0.71) | BIRC5RIPK2SP1ILF3PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118178417-A | Antiproliferative compounds and second active agents for the treatment of multiple myeloma | 细胞基因公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-4171550-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | Celgene Corporation (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-4048260-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | Celgene Corporation (US) | 2022-08-31 | — | — | EP | disclosed |
| CN-114404596-A | Antiproliferative compounds and second agents for the treatment of multiple myeloma | 细胞基因公司 | 2022-04-29 | — | — | CN | disclosed |